- Cullinan Therapeutics recently began submitting a New Drug Application to the FDA under the Real-Time Oncology Review program for zipalertinib plus platinum chemotherapy in previously untreated EGFR exon 20 insertion non small cell lung cancer. The submission is backed by Phase 3 data showing a statistically significant, clinically meaningful progression free survival benefit.
- The filing builds on zipalertinib’s existing Breakthrough Therapy designation and a separate monotherapy NDA already under FDA review. Together, these developments indicate a potential shift from a purely clinical pipeline to a more commercial ready profile if regulatory decisions are favorable.
- We will now look at how Cullinan Therapeutics’ investment narrative could evolve as zipalertinib moves into real time FDA review.
Scan 35 healthcare AI stocks that, like Cullinan Therapeutics, are pushing new therapies toward regulators and could be next in line for market moving clinical milestones.
Cullinan Therapeutics Investment Narrative Recap
To own Cullinan Therapeutics, you need to believe zipalertinib can move from late stage oncology asset to a real commercial product while the autoimmune T cell engager portfolio matures behind it. The real time review NDA adds visibility on a potential first revenue source. The biggest near term swing factor remains how regulators assess the totality of efficacy and safety data for zipalertinib.
The key risk has not changed. Cullinan Therapeutics still has no approved drugs, depends on external funding and carries prior reports of adverse event related deaths for the zipalertinib plus chemotherapy regimen, which could influence any eventual label. If approvals slip or labels are tight, the path toward meaningful revenue becomes harder.
The recent pipeline update for CLN 978, velinotamig and CLN 049 matters here because it shows whether Cullinan Therapeutics is building depth beyond zipalertinib. Fresh data in autoimmune diseases and AML in the fourth quarter of 2026 will help investors judge how realistic a multi asset revenue story could be over time.
Those readouts also sit next to the zipalertinib review as a second set of catalysts. Positive signals in SLE, RA, SjD or AML would support the idea that the current R&D spending and lack of profitability are laying groundwork for future products. Weak or inconclusive data would leave the business more exposed to any disappointment around the zipalertinib NDAs.
Cullinan Therapeutics' current analyst framework points to forecast revenue of US$70.9 million and forecast earnings of US$12.2 million by 2029, which reflects a shift from current earnings of a US$208.3 million loss to a projected profit. This implies an earnings change of roughly US$220 million and assumes that revenue increases from zero to US$70.9 million over that period.
Uncover why Cullinan Therapeutics' fair value indicates a 115% potential upside to its current price, which may not last much longer.
Exploring Other Perspectives
For Cullinan Therapeutics, the biggest swing factor in the alternate, more optimistic story is the autoimmune T cell engager franchise rather than zipalertinib itself. The most upbeat analysts were already penciling in US$148.8 million of revenue and US$25.6 million of earnings by 2029. Your view on this new NDA could shift that narrative, so it helps to compare several angles before deciding on your perspective regarding the stock.
Explore another Cullinan Therapeutics fair value estimate, including one that suggests as much as 115% upside from the current price.
Decide For Yourself
Don't just follow the ticker. Dig into the data and build a conviction that's truly your own.
- A great starting point for your Cullinan Therapeutics research is our analysis highlighting 1 key reward and 3 important warning signs that could impact your investment decision.
- See our latest analysis for Cullinan Therapeutics. The report includes a comprehensive fundamental analysis summarized in a single visual, the Snowflake, making it easy to evaluate Cullinan Therapeutics' overall financial health at a glance.
Looking For More Investment Ideas Beyond Cullinan Therapeutics?
Once you have a view on Cullinan Therapeutics, it can help to widen the lens and compare it with other potential opportunities that fit different portfolio roles using the Simply Wall St Screener.
- If you want higher risk and higher potential payoff situations, scan 12 elite penny stocks with strong financials that might offer sharp moves around clinical, product or financing milestones.
- For investors focused on quality at a sensible price, review a curated 29 high quality undervalued stocks that combine stronger fundamentals with more modest expectations.
- Capital preservation may matter more to you right now, in which case filtering for a 31 resilient stocks with low risk scores can help you narrow in on businesses with more resilient profiles.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com